Precipio (NASDAQ:PRPO) Issues Quarterly Earnings Results

Precipio (NASDAQ:PRPO) posted its quarterly earnings data on Friday. The biotechnology company reported ($0.05) earnings per share for the quarter, Zacks reports. The company had revenue of $6.77 million for the quarter. Precipio had a negative return on equity of 15.00% and a negative net margin of 8.48%.

Precipio Stock Down 0.7%

Precipio stock opened at $19.38 on Friday. The stock’s 50 day moving average price is $19.45 and its 200 day moving average price is $14.68. Precipio has a 1-year low of $3.90 and a 1-year high of $22.38. The company has a market cap of $31.39 million, a PE ratio of -16.28 and a beta of 1.14. The company has a debt-to-equity ratio of 0.05, a current ratio of 0.93 and a quick ratio of 0.69.

Analyst Upgrades and Downgrades

PRPO has been the subject of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Precipio in a research note on Wednesday, October 8th. Wall Street Zen downgraded shares of Precipio from a “buy” rating to a “hold” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Precipio presently has a consensus rating of “Sell”.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.